A Phase II Trial Of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC 716051, IND 61135), And Transplantation For Adults With Newly Diagnosed PH+ Acute Lymphoblastic Leukemia By The CALGB And SWOG.

Trial Profile

A Phase II Trial Of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC 716051, IND 61135), And Transplantation For Adults With Newly Diagnosed PH+ Acute Lymphoblastic Leukemia By The CALGB And SWOG.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2014

At a glance

  • Drugs Imatinib (Primary) ; Cyclophosphamide; Cytarabine; Etoposide; Filgrastim; Folinic acid; Methotrexate; Tacrolimus; Tacrolimus; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top